Visual Field Defect after Taking Atorvastatin/Ezetimibe, a Case Study
Korean Journal of Clinical Pharmacy
;
: 133-137, 2019.
Article
Dans Coréen
| WPRIM
| ID: wpr-759613
ABSTRACT
Atorvastatin is one of the most widely prescribed medications for dyslipidemia treatment. In Korea, post combined therapy with ezetimibe, a 73-year-old woman was reported by a community pharmacy to have experienced visual field defect, which recovered after drug discontinuation. She had never experienced this symptom before, and several studies have reported an association between use of statins and visual disorders such as blurred vision, diplopia, and cataract. Blockage of cholesterol accumulation, oxidative stress, or myopathy is expected to be a cause of this symptom. Naranjo scale, Korean causality assessment algorithm (Ver.2), and World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria were the three tools used to determine causality between the visual disorder and atorvastatin. The results represent ‘probable’, ‘certain’, and ‘probable/likely’ causality, respectively. Our results, in combination with a review of literature, indicate that ocular adverse effects are highly likely related to atorvastatin.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pharmacies
/
Troubles de la vision
/
Cataracte
/
Champs visuels
/
Cholestérol
/
Santé mondiale
/
Stress oxydatif
/
Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase
/
Diplopie
/
Effets secondaires indésirables des médicaments
Limites du sujet:
Adulte très âgé
/
Femelle
/
Humains
Pays comme sujet:
Asie
langue:
Coréen
Texte intégral:
Korean Journal of Clinical Pharmacy
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS